[1] |
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American heart association[J]. Circulation, 2017, 135(17): e927-e999.
|
[2] |
Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. Circ J, 2020, 84(8): 1348-1407.
doi: 10.1253/circj.CJ-19-1094
pmid: 32641591
|
[3] |
Wu MH, Chen HC, Yeh SJ, et al. Prevalence and the long-term coronary risks of patients with Kawasaki disease in a general population <40 years: a national database study[J]. Circ Cardiovasc Qual Outcomes, 2012, 5(4): 566-570.
doi: 10.1161/CIRCOUTCOMES.112.965194
|
[4] |
朱丹颖, 宋思瑞, 张晗, 等. 川崎病丙种球蛋白无反应评分模型的建立与研究[J]. 国际儿科学杂志, 2018, 45(7): 532-536.
|
[5] |
Kobayashi T, Ayusawa M, Suzuki H, et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition)[J]. Pediatr Int, 2020, 62(10): 1135-1138.
doi: 10.1111/ped.v62.10
|
[6] |
Miura M. Follow up of Kawasaki disease based on the nationwide survey data in Japan[J]. Pediatr Int, 2022, 64(1): e15316.
|
[7] |
Kuwabara M, Yashiro M, Kotani K, et al. Cardiac lesions and initial laboratory data in Kawasaki disease: a nationwide survey in Japan[J]. J Epidemiol, 2015, 25(3): 189-193.
doi: 10.2188/jea.JE20140128
pmid: 25716055
|
[8] |
Chen JJ, Ma XJ, Liu F, et al. Epidemiologic features of Kawasaki disease in Shanghai from 2008 through 2012[J]. Pediatr Infect Dis J, 2016, 35(1): 7-12.
doi: 10.1097/INF.0000000000000914
|
[9] |
Xie LP, Yan WL, Huang M, et al. Epidemiologic features of Kawasaki disease in Shanghai From 2013 through 2017[J]. J Epidemiol, 2020, 30(10): 429-435.
doi: 10.2188/jea.JE20190065
|
[10] |
唐玲玲. 川崎病临床特征分析及Z值评估冠状动脉病变的临床意义[D]. 湖北: 湖北医药学院, 2021.
|
[11] |
Seki M, Minami T. Kawasaki disease: pathology, risks, and management[J]. Vasc Health Risk Manag, 2022, 18: 407-416.
doi: 10.2147/VHRM.S291762
pmid: 35711626
|
[12] |
Watanabe M, Fukazawa R, Ogawa S, et al. Virtual histology intravascular ultrasound evaluation of coronary artery lesions within 1 year and more than 10 years after the onset of Kawasaki disease[J]. J Cardiol, 2020, 75(2): 171-176.
doi: S0914-5087(19)30236-9
pmid: 31444141
|
[13] |
Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease[J]. Circulation, 2006, 113(22): 2606-2612.
doi: 10.1161/CIRCULATIONAHA.105.592865
pmid: 16735679
|
[14] |
Son MBF, Gauvreau K, Tremoulet AH, et al. Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a north American population[J]. J Am Heart Assoc, 2019, 8(11): e011319.
|
[15] |
Hua W, Ma F, Wang Y, et al. A new scoring system to predict Kawasaki disease with coronary artery lesions[J]. Clin Rheumatol, 2019, 38(4): 1099-1107.
doi: 10.1007/s10067-018-4393-7
pmid: 30523553
|
[16] |
Türkuçar S, Yıldız K, Acarı C, et al. Risk factors of intravenous immunoglobulin resistance and coronary arterial lesions in Turkish children with Kawasaki disease[J]. Turk J Pediatr. 2020, 62(1): 1-9.
|
[17] |
Zheng X, Wu W, Zhang Y, et al. Changes in and significance of platelet function and parameters in Kawasaki disease[J]. Sci Rep, 2019, 9(1): 17641.
doi: 10.1038/s41598-019-54113-1
pmid: 31776411
|
[18] |
Xia Y, Qiu H, Wen Z, et al. Albumin level and progression of coronary artery lesions in Kawasaki disease: A retrospective cohort study[J]. Front Pediatr, 2022, 10: 947059.
doi: 10.3389/fped.2022.947059
|
[19] |
Yi L, Zhang J, Zhong J, et al. Elevated levels of platelet activating factor and its acetylhydrolase indicate high risk of Kawasaki disease[J]. J Interferon Cytokine Res, 2020, 40(3): 159-167.
doi: 10.1089/jir.2019.0141
|
[20] |
Xu YM, Chu YQ, Wang H. Correlation analysis of anti-cardiolipin antibody/D dimer/C-reactive protein and coronary artery lesions/multiple-organ damage in children with Kawasaki disease[J]. Front Pediatr, 2021, 9: 704929.
doi: 10.3389/fped.2021.704929
|
[21] |
Jeon SK, Kim G, Ko H, et al. Risk factors for the occurrence and persistence of coronary aneurysms in Kawasaki disease[J]. Korean J Pediatr, 2019, 62(4): 138-143.
doi: 10.3345/kjp.2018.07052
|
[22] |
Hirai S, Nakamura T, Misawa M. Predictive potential of age-group cut-off values of N-terminal pro-brain natriuretic peptide in Kawasaki disease[J]. Pediatr Int, 2022, 64(1): e15371.
|
[23] |
Qiu H, Jia C, Wang Z, et al. Prognosis and risk factors of coronary artery lesions before immunoglobulin therapy in children with Kawasaki disease[J]. Balkan Med J, 2020, 37(6): 324-329.
|